We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Structural Proteins Are Linked to Apoptosis Inhibition and Tumor Promotion

By Biotechdaily staff writers
Posted on 04 Aug 2008
Researchers have examined how isoforms of NSP (novel structural protein) are linked to the inhibition of apoptosis and the promotion of tumor growth.

Investigators at Temple University (Philadelphia, PA, USA) worked with a cancer cell line (Hela cells). More...
They used a suite of high tech methods including siRNA silencing and fluorescent cell sorting to manipulate and monitor the activity of various NSP isoforms. In particular, they were interested in the interaction between NSP isoform 5a3a and the nucleolar phosphoprotein B23, a multifunctional protein that is involved in cellular processes such as cell division, DNA repair, and apoptosis.

They reported in the June 15, 2008, issue of the journal Cell Cycle that reducing the expression of NSP5a3a did not affect the cell's viability or prevent it from proliferating. However, when B23 expression was lowered, most of the cells in the culture moved towards apoptosis. When the expression of both proteins was lowered simultaneously, no apoptosis occurred. Loss of apoptosis is a critical step in the transformation of normal to cancerous cells.

"So far, we have been able to confirm that two of the NSPs' four isoforms, called NSP 5a3a and NSP 5a3b, interact with a protein called B23, a multifunctional protein that is involved in cellular processes such as cell division, DNA repair and apoptosis,” said first author Dr. Luca D'Agostino, a research fellow at Temple University. "Eventually, we have to screen different types of cancers, different grades, and stages, to see if there is a difference in the expression of NSP5a3a and 5a3b, and if they have an application in the clinical field. With the 5a3a, if we see a pattern of expression when we do screenings of tissue biopsies, it could be useful as a diagnostic tool.”


Related Links:
Temple University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.